The primary target audience for this meeting comprise the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; pharmacists; physician assistants; and other allied health care professionals.
ASCO DIRECT™ HIGHLIGHTS condense the most cutting-edge science and education from the world’s premier oncology event, the ASCO Annual Meeting. The abstracts chosen for presentation and discussion reflect state-of-the-art developments and recent advances in oncology that will directly impact patient care. The program features in-depth discussion and analysis on the latest scientific findings in primary disease sites and practice-changing advances in cancer treatment. Expert faculty place abstract findings into clinical context and discuss how the results may change the current standard of care.
At the end of this educational activity, participants should be able to:
Jeffrey Gregg, MD
Senior Director, Clinical Pathology
Director, Molecular Diagnostics
Professor of Pathology
Department of Pathology and Laboratory Medicine
University of California, Davis Medical Center
Scientific Advisor, Liquid Biopsy
Foundation Medicine, Inc.
This activity is supported in part by educational grants from Astellas and Seattle Genetics, Amgen, Celgene Corporation, Daiichi Sankyo, Inc., Lilly, Merck & Co., Inc. and TESARO, Inc.